http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16725058

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Research Support, Non-U.S. Gov't
endingPage 1405
issn 1573-0646
0167-6997
issueIdentifier 6
pageRange 1395-1405
publicationName Investigational New Drugs
startingPage 1395
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_22eea0c588aa956d15373bef9ee7922c
bibliographicCitation LoRusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Investigational New Drugs. 2010 Jul 06;29(6):1395–405. doi: 10.1007/s10637-010-9484-5.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a96d8baf22fb444cf3e49c7ffb33c5be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec603cc362e2f3072fc379017bcbaed7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25dce08d8f6afaec8954ebb848ec9140
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2cbeb28872e3217cecff354eeab784d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5800-4571
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e349970854e3b9b5d1fe8bce416e3af9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e9b726db4d3023184926edf8bda2f597
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23361fd32abe2ac8796a11dd816b2c51
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1975ed6ab3e2884ebd49de1133c3b7a
date 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/20607586
https://doi.org/10.1007/s10637-010-9484-5
https://pubmed.ncbi.nlm.nih.gov/PMC4102931
isPartOf https://portal.issn.org/resource/ISSN/0167-6997
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
https://portal.issn.org/resource/ISSN/1573-0646
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study
discusses http://id.nlm.nih.gov/mesh/M0185203
http://id.nlm.nih.gov/mesh/M0485541
http://id.nlm.nih.gov/mesh/M0018336
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9933475
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129754723
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288

Total number of triples: 48.